116 related articles for article (PubMed ID: 11412980)
1. Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
Curtin ML; Florjancic AS; Heyman HR; Michaelides MR; Garland RB; Holms JH; Steinman DH; Dellaria JF; Gong J; Wada CK; Guo Y; Elmore IB; Tapang P; Albert DH; Magoc TJ; Marcotte PA; Bouska JJ; Goodfellow CL; Bauch JL; Marsh KC; Morgan DW; Davidsen SK
Bioorg Med Chem Lett; 2001 Jun; 11(12):1557-60. PubMed ID: 11412980
[TBL] [Abstract][Full Text] [Related]
2. Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.
Michaelides MR; Dellaria JF; Gong J; Holms JH; Bouska JJ; Stacey J; Wada CK; Heyman HR; Curtin ML; Guo Y; Goodfellow CL; Elmore IB; Albert DH; Magoc TJ; Marcotte PA; Morgan DW; Davidsen SK
Bioorg Med Chem Lett; 2001 Jun; 11(12):1553-6. PubMed ID: 11412979
[TBL] [Abstract][Full Text] [Related]
3. Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
Wada CK; Holms JH; Curtin ML; Dai Y; Florjancic AS; Garland RB; Guo Y; Heyman HR; Stacey JR; Steinman DH; Albert DH; Bouska JJ; Elmore IN; Goodfellow CL; Marcotte PA; Tapang P; Morgan DW; Michaelides MR; Davidsen SK
J Med Chem; 2002 Jan; 45(1):219-32. PubMed ID: 11754593
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and activity of selective MMP inhibitors with an aryl backbone.
Barta TE; Becker DP; Bedell LJ; De Crescenzo GA; McDonald JJ; Munie GE; Rao S; Shieh HS; Stegeman R; Stevens AM; Villamil CI
Bioorg Med Chem Lett; 2000 Dec; 10(24):2815-7. PubMed ID: 11133099
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.
Xue CB; Voss ME; Nelson DJ; Duan JJ; Cherney RJ; Jacobson IC; He X; Roderick J; Chen L; Corbett RL; Wang L; Meyer DT; Kennedy K; DeGradodagger WF; Hardman KD; Teleha CA; Jaffee BD; Liu RQ; Copeland RA; Covington MB; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2001 Aug; 44(16):2636-60. PubMed ID: 11472217
[TBL] [Abstract][Full Text] [Related]
6. Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.
Duan JJ; Chen L; Wasserman ZR; Lu Z; Liu RQ; Covington MB; Qian M; Hardman KD; Magolda RL; Newton RC; Christ DD; Wexler RR; Decicco CP
J Med Chem; 2002 Nov; 45(23):4954-7. PubMed ID: 12408705
[TBL] [Abstract][Full Text] [Related]
7. Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species.
Sandhu P; Andrews PA; Baker MP; Koeplinger KA; Soli ED; Miller T; Baillie TA
Drug Metab Lett; 2007 Apr; 1(2):153-61. PubMed ID: 19356036
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.
Yao W; Wasserman ZR; Chao M; Reddy G; Shi E; Liu RQ; Covington MB; Arner EC; Pratta MA; Tortorella M; Magolda RL; Newton R; Qian M; Ribadeneira MD; Christ D; Wexler RR; Decicco CP
J Med Chem; 2001 Oct; 44(21):3347-50. PubMed ID: 11585439
[TBL] [Abstract][Full Text] [Related]
9. Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
Baxter AD; Bhogal R; Bird J; Keily JF; Manallack DT; Montana JG; Owen DA; Pitt WR; Watson RJ; Wills RE
Bioorg Med Chem Lett; 2001 Jun; 11(11):1465-8. PubMed ID: 11378378
[TBL] [Abstract][Full Text] [Related]
10. The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199.
Choo EF; Boggs J; Zhu C; Lubach JW; Catron ND; Jenkins G; Souers AJ; Voorman R
Drug Metab Dispos; 2014 Feb; 42(2):207-12. PubMed ID: 24212376
[TBL] [Abstract][Full Text] [Related]
11. alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.
Becker DP; DeCrescenzo G; Freskos J; Getman DP; Hockerman SL; Li M; Mehta P; Munie GE; Swearingen C
Bioorg Med Chem Lett; 2001 Oct; 11(20):2723-5. PubMed ID: 11591510
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel farnesyltransferase inhibitor.
Lin NH; Wang L; Wang X; Wang GT; Cohen J; Gu WZ; Zhang H; Rosenberg SH; Sham HL
Bioorg Med Chem Lett; 2004 Oct; 14(20):5057-62. PubMed ID: 15380198
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.
Zask A; Gu Y; Albright JD; Du X; Hogan M; Levin JI; Chen JM; Killar LM; Sung A; DiJoseph JF; Sharr MA; Roth CE; Skala S; Jin G; Cowling R; Mohler KM; Barone D; Black R; March C; Skotnicki JS
Bioorg Med Chem Lett; 2003 Apr; 13(8):1487-90. PubMed ID: 12668018
[TBL] [Abstract][Full Text] [Related]
14. Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.
Song J; Peng P; Chang J; Liu MM; Yu JM; Zhou L; Sun X
Bioorg Med Chem Lett; 2016 May; 26(9):2174-8. PubMed ID: 27038494
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
16. 5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.
Ballard P; Bradbury RH; Hennequin LF; Hickinson DM; Johnson PD; Kettle JG; Klinowska T; Morgentin R; Ogilvie DJ; Olivier A
Bioorg Med Chem Lett; 2005 Oct; 15(19):4226-9. PubMed ID: 16055332
[TBL] [Abstract][Full Text] [Related]
17. Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach.
Chen D; Hackbarth C; Ni ZJ; Wu C; Wang W; Jain R; He Y; Bracken K; Weidmann B; Patel DV; Trias J; White RJ; Yuan Z
Antimicrob Agents Chemother; 2004 Jan; 48(1):250-61. PubMed ID: 14693547
[TBL] [Abstract][Full Text] [Related]
18. Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Ott GR; Asakawa N; Liu RQ; Covington MB; Qian M; Vaddi K; Newton RC; Trzaskos JM; Christ DD; Galya L; Scholz T; Marshall W; Duan JJ
Bioorg Med Chem Lett; 2008 Feb; 18(4):1288-92. PubMed ID: 18234496
[TBL] [Abstract][Full Text] [Related]
19. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Price S; Bordogna W; Bull RJ; Clark DE; Crackett PH; Dyke HJ; Gill M; Harris NV; Gorski J; Lloyd J; Lockey PM; Mullett J; Roach AG; Roussel F; White AB
Bioorg Med Chem Lett; 2007 Jan; 17(2):370-5. PubMed ID: 17095213
[TBL] [Abstract][Full Text] [Related]
20. Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 2: the synthesis and biological activities of RPR127963 an orally bioavailable inhibitor.
He W; Myers MR; Hanney B; Spada AP; Bilder G; Galzcinski H; Amin D; Needle S; Page K; Jayyosi Z; Perrone MH
Bioorg Med Chem Lett; 2003 Sep; 13(18):3097-100. PubMed ID: 12941342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
